ABVC BioPharma, Inc. (NASDAQ:ABVC) Sees Significant Drop in Short Interest

ABVC BioPharma, Inc. (NASDAQ:ABVCGet Free Report) was the target of a significant drop in short interest during the month of January. As of January 15th, there was short interest totalling 360,300 shares, a drop of 42.6% from the December 31st total of 628,000 shares. Currently, 3.2% of the company’s shares are sold short. Based on an average daily volume of 266,100 shares, the short-interest ratio is presently 1.4 days.

ABVC BioPharma Stock Performance

ABVC BioPharma stock opened at $0.52 on Friday. The company has a 50 day moving average price of $0.54 and a 200-day moving average price of $0.62. ABVC BioPharma has a fifty-two week low of $0.41 and a fifty-two week high of $1.73. The company has a market capitalization of $6.75 million, a PE ratio of -0.60 and a beta of 0.70.

ABVC BioPharma Company Profile

(Get Free Report)

ABVC BioPharma, Inc, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients.

Featured Stories

Receive News & Ratings for ABVC BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABVC BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.